Cargando…
The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors?
RATIONALE: The use of cisplatin in patients with chronic kidney disease (CKD) is risky and depends on a number of factors. The optimal procedure in stage I of a non seminomatous germ cell tumor without proven lymphangioinvasion after orchiectomy is controversial and is the subject of a number of dis...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213256/ https://www.ncbi.nlm.nih.gov/pubmed/34128899 http://dx.doi.org/10.1097/MD.0000000000026381 |
_version_ | 1783709806267203584 |
---|---|
author | Pokrivcak, Tomas Lakomy, Radek Kazda, Tomas Poprach, Alexandr Fabian, Pavel Kiss, Igor |
author_facet | Pokrivcak, Tomas Lakomy, Radek Kazda, Tomas Poprach, Alexandr Fabian, Pavel Kiss, Igor |
author_sort | Pokrivcak, Tomas |
collection | PubMed |
description | RATIONALE: The use of cisplatin in patients with chronic kidney disease (CKD) is risky and depends on a number of factors. The optimal procedure in stage I of a non seminomatous germ cell tumor without proven lymphangioinvasion after orchiectomy is controversial and is the subject of a number of discussions due to the lack of randomized studies assessing individual treatment options. The adjuvant method of choice is surveillance or application of cisplatin-based chemotherapy with the risk of treatment related nephrotoxicity. Information about cisplatin safety in renal transplant patients is particularly limited. The aim of this paper is to share the experience with the application of adjuvant chemotherapy Bleomycin, Etoposide, Cisplatin (BEP) in high-risk patient with nonseminoma after kidney transplantation. PATIENT CONCERNS: We report a case report of rare group of high-risk patient with non-seminomatous germ cell testicular tumor (NSGCT) after kidney transplantation before application of adjuvant chemotherapy BEP. Patient presented with month-long discomfort in the scrotal area. Previously, he was treated with chronic kidney disease based on chronic glomerulonephritis, which was treated with repeated kidney transplantation. DIAGNOSIS: The ultrasound examination for a month-long discomfort in the scrotal area found a solid mass of the left testis. Radical inguinal orchiectomy confirmed NSGCT with the presence of lymphovascular invasion (LVI). Postoperative staging with computed tomography of the chest and abdomen did not show obvious dissemination of the disease. INTERVENTIONS: Reducing original dose of chemotherapeutics according to the recommendations of the summary of product characteristics led to only a transient increase in creatinine levels. OUTCOMES: The 5-year risk of relapse in surveillance was reduced to around 3% by applying cisplatin-based chemotherapy. LESSONS: Application of cisplatin-based chemotherapy is safe and effective in patients with CKD and in patients with a kidney transplant. |
format | Online Article Text |
id | pubmed-8213256 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-82132562021-06-21 The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors? Pokrivcak, Tomas Lakomy, Radek Kazda, Tomas Poprach, Alexandr Fabian, Pavel Kiss, Igor Medicine (Baltimore) 5700 RATIONALE: The use of cisplatin in patients with chronic kidney disease (CKD) is risky and depends on a number of factors. The optimal procedure in stage I of a non seminomatous germ cell tumor without proven lymphangioinvasion after orchiectomy is controversial and is the subject of a number of discussions due to the lack of randomized studies assessing individual treatment options. The adjuvant method of choice is surveillance or application of cisplatin-based chemotherapy with the risk of treatment related nephrotoxicity. Information about cisplatin safety in renal transplant patients is particularly limited. The aim of this paper is to share the experience with the application of adjuvant chemotherapy Bleomycin, Etoposide, Cisplatin (BEP) in high-risk patient with nonseminoma after kidney transplantation. PATIENT CONCERNS: We report a case report of rare group of high-risk patient with non-seminomatous germ cell testicular tumor (NSGCT) after kidney transplantation before application of adjuvant chemotherapy BEP. Patient presented with month-long discomfort in the scrotal area. Previously, he was treated with chronic kidney disease based on chronic glomerulonephritis, which was treated with repeated kidney transplantation. DIAGNOSIS: The ultrasound examination for a month-long discomfort in the scrotal area found a solid mass of the left testis. Radical inguinal orchiectomy confirmed NSGCT with the presence of lymphovascular invasion (LVI). Postoperative staging with computed tomography of the chest and abdomen did not show obvious dissemination of the disease. INTERVENTIONS: Reducing original dose of chemotherapeutics according to the recommendations of the summary of product characteristics led to only a transient increase in creatinine levels. OUTCOMES: The 5-year risk of relapse in surveillance was reduced to around 3% by applying cisplatin-based chemotherapy. LESSONS: Application of cisplatin-based chemotherapy is safe and effective in patients with CKD and in patients with a kidney transplant. Lippincott Williams & Wilkins 2021-06-18 /pmc/articles/PMC8213256/ /pubmed/34128899 http://dx.doi.org/10.1097/MD.0000000000026381 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | 5700 Pokrivcak, Tomas Lakomy, Radek Kazda, Tomas Poprach, Alexandr Fabian, Pavel Kiss, Igor The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors? |
title | The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors? |
title_full | The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors? |
title_fullStr | The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors? |
title_full_unstemmed | The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors? |
title_short | The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors? |
title_sort | use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors? |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213256/ https://www.ncbi.nlm.nih.gov/pubmed/34128899 http://dx.doi.org/10.1097/MD.0000000000026381 |
work_keys_str_mv | AT pokrivcaktomas theuseofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors AT lakomyradek theuseofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors AT kazdatomas theuseofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors AT poprachalexandr theuseofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors AT fabianpavel theuseofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors AT kissigor theuseofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors AT pokrivcaktomas useofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors AT lakomyradek useofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors AT kazdatomas useofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors AT poprachalexandr useofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors AT fabianpavel useofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors AT kissigor useofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors |